Company intelligence / Profile preview

Santair

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Santaris developed a pipeline of LNA-based antisense drugs targeting mRNA and microRNAs for cancer, infectious diseases, metabolic disorders, and rare genetic conditions. Lead programs included SPC3649 for Hepatitis C in Phase 1/2 trials. The company’s technology attracted major pharma partnerships but did not reach commercial stage before acquisition by Roche.

Therapeutic areas: OncologyMetabolic DisordersRare DiseasesInfectious Diseases
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

GlaxoSmithKline – global R&D partnership on viral diseasesShire – strategic alliance on rare genetic disease drugsEnzon Pharmaceuticals – collaboration on oncology therapeuticsPfizer – research collaborationmiRagen Therapeutics – research collaboration

Beyond the preview

Go deeper on Santair.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santair.

Explore the full profile